InvestSMART

Percheron Therapeutics Limited (ASX: PER) - Announcements

Current share price for PER : $0.006 0.001 (20%)+

ASX company news and announcements for Percheron Therapeutics Limited (PER) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Percheron Therapeutics Limited (PER) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Percheron Therapeutics Limited (PER), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Percheron Therapeutics Limited (PER)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$9 Application for quotation of securities - PER 7 Sep 2026 8:25AM $0.005 $0.006 risen by 20%
$9 2026 Notice of Annual General Meeting 7 Sep 2026 8:24AM $0.005 $0.006 risen by 20%
$9 Percheron Therapeutics Limited Corporate Presentation 1 Sep 2026 11:01AM $0.006 $0.006 fallen by 0%
$9 Proposed issue of securities - PER 1 Sep 2026 9:23AM $0.005 $0.006 risen by 20%
$9 Proposed issue of securities - PER 1 Sep 2026 9:23AM $0.005 $0.006 risen by 20%
$9 Proposed issue of securities - PER 1 Sep 2026 9:23AM $0.005 $0.006 risen by 20%
$9 Percheron raises $2.3m to fully fund clinical trial in AML 1 Sep 2026 9:23AM $0.005 $0.006 risen by 20%
$9 Initial Director's Interest Notice 31 Aug 2026 5:24PM $0.005 $0.006 risen by 20%
$9 Transitional appointment of Executive Director 31 Aug 2026 5:22PM $0.005 $0.006 risen by 20%
$9 Change of Director's Interest Notice 31 Aug 2026 5:02PM $0.005 $0.006 risen by 20%
$9 Notification of cessation of securities - PER 31 Aug 2026 5:01PM $0.005 $0.006 risen by 20%
$9 Percheron receives $0.70m R&D Tax Incentive Rebate 31 Aug 2026 12:06PM $0.005 $0.006 risen by 20%
$9 Trading Halt 28 Aug 2026 9:01AM $0.005 $0.006 risen by 20%
$9 Vanderbilt Health to conduct clinical trial of HMBD-002 28 Aug 2026 8:11AM $0.005 $0.006 risen by 20%
$9 Appendix 4E and Annual Report 19 Aug 2026 5:24PM $0.006 $0.006 risen by 9.09%
$9 Appendix 4G and Corporate Governance Statement 19 Aug 2026 11:38AM $0.005 $0.006 risen by 20%
$9 Appendix 4E and Annual Report 19 Aug 2026 11:33AM $0.005 $0.006 risen by 20%
$9 Application for quotation of securities - PER 14 Aug 2026 2:46PM $0.005 $0.006 risen by 20%
$9 Notice of date of AGM and other relevant dates 12 Aug 2026 8:16AM $0.003 $0.006 risen by 100%
$9 Percheron Therapeutics Announces CEO Succession 10 Aug 2026 8:24AM $0.003 $0.006 risen by 100%
$9 Quarterly Activities Report and Appendix 4C 31 Jul 2026 8:29AM $0.003 $0.006 risen by 100%
$9 Notification regarding unquoted securities - PER 3 Jul 2026 4:21PM $0.004 $0.006 risen by 71.43%
$9 Completion of HMBD-002 Drug Substance Manufacture 17 Jun 2026 8:22AM $0.005 $0.006 risen by 33.33%
$9 New HMBD-002 Data Presented at ASCO Annual Meeting 2 Jun 2026 8:22AM $0.005 $0.006 risen by 33.33%
$9 Notification regarding unquoted securities - PER 1 Jun 2026 3:41PM $0.005 $0.006 risen by 33.33%

1 - 25 of 199 results

Page 1 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.